Parallel Advisors’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Parallel Advisors’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-281	Closed	-$7K	–	2339
2018 Q3	$7K	Buy	+281	New	+$8.23K	﹤0.01%	1614

Other funds holding CYAD

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Parallel Advisors's CYAD Position: Q4 2018 in Review

Parallel Advisors sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q4 2018, closing a stake of 281 shares — an estimated $7K sold.

Parallel Advisors first reported a position in CYAD in Q3 2018 and held it in 1 quarter. The position peaked at $7K in Q3 2018. 8 funds tracked by Wall St. Rank hold CYAD as of Q4 2018.

Parallel Advisors reported no remaining Celyad Oncology SA American Depositary Shares position as of Q4 2018 after selling out during the quarter.
Parallel Advisors sold 281 Celyad Oncology SA American Depositary Shares shares in Q4 2018, an estimated $7K.
Parallel Advisors first reported a position in Celyad Oncology SA American Depositary Shares in Q3 2018 and held it in 1 quarter.
Parallel Advisors's Celyad Oncology SA American Depositary Shares position peaked at $7K in Q3 2018.
8 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q4 2018.

Based on Parallel Advisors's 13F filing for Q4 2018, filed 5 Feb 2019.